New COPD Candidates Could Get Hung Up On Safety Concerns
FDA is facing several novel candidates for chronic obstructive pulmonary disease in 2013; those products should expect close scrutiny due to past issues with class safety and new signals in clinical trials.
You may also be interested in...
The Canadian company will use the funds from its Series C financing to advance its lead drug candidate through Phase II testing in two indications, including COPD.
FDA missed its deadline to post the advisory committee briefing materials then postponed the meeting as a winter storm headed towards Washington.
Quintiles files IPO; Forest sees LAMA/LABA combo product, slated for a 2014 NDA, as filling out a suite of COPD drugs to cover the full range of disease severity. Plus news from a host of biopharma quarterly earnings calls.